A Nonazole CYP51 Inhibitor Cures Chagas’ Disease in a Mouse Model of Acute Infection

ABSTRACT Chagas’ disease, the leading cause of heart failure in Latin America, is caused by the kinetoplastid protozoan Trypanosoma cruzi. The sterols of T. cruzi resemble those of fungi, both in composition and in biosynthesis. Azole inhibitors of sterol 14α-demethylase (CYP51) successfully treat fungal infections in humans, and efforts to adapt the success of antifungal azoles posaconazole and ravuconazole as second-use agents for Chagas’ disease are under way. However, to address concerns about the use of azoles for Chagas’ disease, including drug resistance and cost, the rational design of nonazole CYP51 inhibitors can provide promising alternative drug chemotypes. We report the curative effect of the nonazole CYP51 inhibitor LP10 in an acute mouse model of T. cruzi infection. Mice treated with an oral dose of 40 mg LP10/kg of body weight twice a day (BID) for 30 days, initiated 24 h postinfection, showed no signs of acute disease and had histologically normal tissues after 6 months. A very stringent test of cure showed that 4/5 mice had negative PCR results for T. cruzi, and parasites were amplified by hemoculture in only two treated mice. These results compare favorably with those reported for posaconazole. Electron microscopy and gas chromatography-mass spectrometry (GC-MS) analysis of sterol composition confirmed that treatment with LP10 blocked the 14α-demethylation step and induced breakdown of parasite cell membranes, culminating in severe ultrastructural and morphological alterations and death of the clinically relevant amastigote stage of the parasite.

[1]  R. Isturiz,et al.  Chagas Disease , 2021, Neglected Tropical Diseases.

[2]  J. Urbina,et al.  Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. , 1999, Molecular and biochemical parasitology.

[3]  J. McKerrow,et al.  Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.

[4]  P. Wincker,et al.  Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870 , 1996, Science.

[5]  E. Mellado,et al.  Substitutions at Methionine 220 in the 14α-Sterol Demethylase (Cyp51A) of Aspergillus fumigatus Are Responsible for Resistance In Vitro to Azole Antifungal Drugs , 2004, Antimicrobial Agents and Chemotherapy.

[6]  D. Loebenberg,et al.  Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding , 2004, Antimicrobial Agents and Chemotherapy.

[7]  D. Denning,et al.  Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure , 2009, Emerging infectious diseases.

[8]  R. Gazzinelli,et al.  The Anti-Trypanosoma cruzi Activity of Posaconazole in a Murine Model of Acute Chagas' Disease Is Less Dependent on Gamma Interferon than That of Benznidazole , 2007, Antimicrobial Agents and Chemotherapy.

[9]  F. Buckner,et al.  Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. , 2008, Advances in experimental medicine and biology.

[10]  Kai Zhu,et al.  Multiscale Optimization of a Truncated Newton Minimization Algorithm and Application to Proteins and Protein-Ligand Complexes. , 2007, Journal of chemical theory and computation.

[11]  Z. Mackey,et al.  Drugs targeting parasite lysosomes. , 2008, Current pharmaceutical design.

[12]  G. Espinosa,et al.  Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. , 2010, The American journal of tropical medicine and hygiene.

[13]  S. Boyle,et al.  Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. , 2003, Molecular and biochemical parasitology.

[14]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[15]  M. Ghannoum,et al.  Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods , 2009, Journal of Clinical Microbiology.

[16]  Carlos M. Morel,et al.  Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis , 1993, Journal of clinical microbiology.

[17]  H. Majumder.  Drug Targets in Kinetoplastid Parasites , 2008 .

[18]  D. Loebenberg,et al.  Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. , 2003, The Journal of antimicrobial chemotherapy.

[19]  P. Wincker,et al.  Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo Studies , 1998, Antimicrobial Agents and Chemotherapy.

[20]  A. Rahier,et al.  Properties and structural requirements for substrate specificity of cytochrome P-450-dependent obtusifoliol 14 alpha-demethylase from maize (Zea mays) seedlings. , 1991, The Biochemical journal.

[21]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[22]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[23]  A. Romanha,et al.  Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. , 2003, International journal of antimicrobial agents.

[24]  J. Cazzulo,et al.  End products and enzyme levels of aerobic glucose fermentation in trypanosomatids. , 1985, Molecular and biochemical parasitology.

[25]  R. Magolda,et al.  Lanosterol 14 alpha-methyl demethylase. Isolation and characterization of the third metabolically generated oxidative demethylation intermediate. , 1991, The Journal of biological chemistry.

[26]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[27]  S. Boyle,et al.  Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylase , 2003 .

[28]  R. Nicasioherrera.  [CLINICAL ASPECTS OF CHAGAS' HEART DISEASE]. , 1963, El Dia medico.

[29]  G. Goldman,et al.  In Vitro Evolution of Itraconazole Resistance in Aspergillus fumigatus Involves Multiple Mechanisms of Resistance , 2004, Antimicrobial Agents and Chemotherapy.

[30]  M. Gelb,et al.  The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. , 2005, Journal of medicinal chemistry.

[31]  D. Rice,et al.  Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. , 2003, Molecular and biochemical parasitology.

[32]  R. McCabe.  Failure of ketoconazole to cure chronic murine Chagas' disease. , 1988, The Journal of infectious diseases.

[33]  J. McKerrow,et al.  A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection , 2007, Antimicrobial Agents and Chemotherapy.

[34]  D. Loebenberg,et al.  Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to Azoles , 2004, Antimicrobial Agents and Chemotherapy.

[35]  S. Costa-de-Oliveira,et al.  Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles. , 2009, FEMS yeast research.

[36]  D. Loebenberg,et al.  Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase , 2003, Antimicrobial Agents and Chemotherapy.

[37]  M. Morris,et al.  Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[38]  T. C. White,et al.  Induction of Resistance to Azole Drugs inTrypanosoma cruzi , 1998, Antimicrobial Agents and Chemotherapy.

[39]  Michael P Barrett,et al.  Chemotherapy of trypanosomiases and leishmaniasis. , 2005, Trends in parasitology.

[40]  E. Mellado,et al.  Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus , 2008, Antimicrobial Agents and Chemotherapy.

[41]  Z. Wan,et al.  Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. , 2005, The Journal of antimicrobial chemotherapy.

[42]  G. Goldman,et al.  Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole , 2003, Antimicrobial Agents and Chemotherapy.

[43]  Siegfried S. F. Leung,et al.  Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole , 2010, PLoS neglected tropical diseases.

[44]  K. Ang,et al.  Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit , 2009, PLoS neglected tropical diseases.

[45]  J. Bennett,et al.  Update on Azole Antifungals , 2008, Seminars in respiratory and critical care medicine.

[46]  J. Cazzulo,et al.  Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimastigotes. , 1987, Molecular and biochemical parasitology.

[47]  E. Mellado,et al.  A Point Mutation in the 14α-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus , 2003, Antimicrobial Agents and Chemotherapy.

[48]  P. Rosenthal,et al.  Development of protease inhibitors for protozoan infections , 2008, Current opinion in infectious diseases.

[49]  M. Waterman,et al.  Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography , 2007, Antimicrobial Agents and Chemotherapy.